Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
:RYTM
RESEARCH TOOLSreports
Holding RYTM?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.69Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: -2.83%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with steady revenue growth, significant international expansion, and promising clinical data, particularly in hypothalamic obesity. However, challenges remain in managing high expenses and patient retention.Company Guidance
During the Rhythm Pharmaceuticals Q3 2024 earnings call, significant guidance was provided regarding their financial performance and strategic focus. The company reported net revenue from global sales of IMCIVREE at $33.3 million, marking a 14% sequential increase from the previous quarter, with U.S. sales accounting for $23.3 million (70% of total revenue) and international sales contributing $10 million (30%). The gross margin was maintained with cost of sales at 11.5% of net product revenue. R&D expenses for the quarter were $37.9 million, while SG&A expenses amounted to $35.4 million. Rhythm adjusted its 2024 OpEx guidance to $245 million to $255 million and affirmed that its cash reserves of $298.4 million are sufficient to fund operations well into 2026. The company remains focused on expanding IMCIVREE's market presence, particularly for Bardet-Biedl Syndrome (BBS) and hypothalamic obesity (HO), and is preparing for potential label expansions to include younger patients. Additionally, Rhythm highlighted ongoing advancements in their MC4R agonist pipeline, with key milestones, including the anticipated top-line data from the Phase III HO trial, expected in the first half of 2025.Steady Revenue Growth
IMCIVREE revenues for the third quarter were $33.3 million, marking a 14% growth over the second quarter of this year. U.S. revenue saw an 8% increase sequentially.
International Expansion
IMCIVREE is now available in more than 15 countries outside the U.S., with initial launches in Spain and Italy progressing well.
Positive Clinical Progress
The Phase III trial in acquired hypothalamic obesity is on track with a dropout rate under 10%. The Japanese cohort is expected to be fully enrolled by year-end.
Encouraging Real-World HO Data
Real-world data from French patients with hypothalamic obesity showed consistent and robust weight loss, with a 21.3% decrease in BMI at 6 months.
Pipeline Advancements
Progress continues with the MC4R agonist pipeline and new expansion opportunities in genetic indications are being explored.
---
RYTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RYTM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $56.25 | $62.65 | +11.38% |
| Aug 06, 2024 | $44.03 | $44.04 | +0.02% |
| May 07, 2024 | $43.88 | $39.35 | -10.32% |
| Feb 22, 2024 | $48.81 | $44.06 | -9.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Rhythm Pharmaceuticals (RYTM) report earnings?
Rhythm Pharmaceuticals (RYTM) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Rhythm Pharmaceuticals (RYTM) earnings time?
Rhythm Pharmaceuticals (RYTM) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RYTM EPS forecast?
RYTM EPS forecast for the fiscal quarter 2024 (Q4) is -0.69.
---